Related Experiment Video
Updated: Aug 18, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Curve models for comparative phase III trials: heterogeneity of the population
Abstract:
Equations were calculated to describe survival on disease-free survival (DFS) curves related to control or adjuvant-therapy-treated patients. They allowed us to differentiate three different segments or populations in the survival curve on a semi-log scale describing high-risk, intermediate-risk and low-risk groups. The percentage of patients and the annual mortality in each risk group could be calculated from the coefficients of the equation. As an example, the DFS curves of the premenopausal breast cancer patients of the Milan group were composed of three segments in the control group and of two segments in the CMF-treated group.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Analysis of Population Pharmacokinetic Data
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Bioequivalence Data: Statistical Interpretation
Comparing the Survival Analysis of Two or More Groups

